A number of pathogens, including the causative agents of tuberculosis and malaria, synthesize isopentenyl diphosphate via the 2-C-methyl-d-erythritol 4-phosphate (MEP) pathway rather than the classical mevalonate pathway found in humans. As part of a structure-based drug-discovery program against tuberculosis, IspD, the enzyme that carries out the third step in the MEP pathway, was targeted. Constructs of both the Mycobacterium smegmatis and the Mycobacterium tuberculosis enzymes that were suitable for structural and inhibitor-screening studies were engineered. Two crystal structures of the M. smegmatis enzyme were produced, one in complex with CTP and the other in complex with CMP. In addition, the M. tuberculosis enzyme was crystallized in complex with CTP. Here, the structure determination and crystallographic refinement of these crystal forms and the enzymatic characterization of the M. tuberculosis enzyme construct are reported. A comparison with known IspD structures allowed the definition of the structurally conserved core of the enzyme. It indicates potential flexibility in the enzyme and in particular in areas close to the active site. These well behaved constructs provide tools for future target-based screening of potential inhibitors. The conserved nature of the extended active site suggests that any new inhibitor will potentially exhibit broad-spectrum activity.
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Introduction
Isopentenyl diphosphate (IPP) is an activated isoprene unit that is a key building block of isoprenoids, a large class of compounds that are essential to all living organisms. In the classical mevalonate pathway, activated acetate in the form of acetyl coenzyme A is converted to IPP in a four-step process that proceeds via the intermediate mevalonate (Beytía & Porter, 1976) . The synthesis of mevalonate is the committed step in cholesterol formation and the enzyme involved is the site of action of the statin class of drugs that reduce plasma cholesterol levels. The discovery of an alternative (nonmevalonate or MEP) pathway (Rohmer, 1999) in Gramnegative and some Gram-positive bacteria, as well as in plant chloroplasts and algae, was met with some excitement, since a number of serious pathogens synthesize IPP by this pathway alone. The conversion of pyruvate and glyceraldehyde 3-phosphate to IPP in seven steps thus offers the opportunity to develop a new series of drugs and herbicides targeting enzymes that are absent in humans. This hope was strengthened when it became clear that the antimalarial drug fosmidomycin targets DXR/IspC (Kuzuyama et al., 1998; Zeidler et al., 1998) , the enzyme that catalyses the second, committed step in the pathway in which 1-deoxy-d-xylulose 5phosphate (DXP) is converted to 2-C-methyl-d-erythritol 4-phosphate (MEP). The antibacterial activity of fosmidomycin, however, was discovered before the MEP pathway was identified (Shigi, 1989) . A great deal of effort has gone into characterizing the MEP pathway to create the framework necessary for target-based drug discovery, but so far it has met with limited success in the development of new medically relevant inhibitors.
Approximately one third of the population of the world is infected with Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), and it is estimated that two million people die every year from the disease. It has been fifty years since the discovery of rifampicin (Sensi et al., 1959) , one of the first-line drugs that are now becoming ineffective as drugresistant forms of the disease emerge. Ten candidate drugs are in clinical trials, but the drug-discovery pipeline needs new compounds and new targets to meet future needs for treatment (Ma et al., 2010) . Because isoprenoid synthesis in mycobacteria takes place via the MEP pathway, this pathway is an attractive source of potential targets for drug discovery against TB. The lack of success in turning DXR inhibitors into compounds with activity towards Mtb, despite a well defined high-resolution structure of the fosmidomycin-DXR complex (Henriksson et al., 2007) , has been attributed to poor uptake (Brown & Parish, 2008) and has shifted attention to other targets in the pathway. IspD (EC 2.7.7.60) is a cytidyl transferase that catalyzes the third reaction in the pathway, in which MEP is converted to 4-diphosphocytidyl-2-C-methyld-erythritol (CDP-ME; Fig. 1 ). The essentiality of IspD in Mtb has been confirmed both by transposon mutagenesis (Sassetti et al., 2003) and by more focused studies (Eoh et al., 2007) . As a first step in a target-based approach to drug discovery, we needed to be able to produce active enzyme and determine its crystal structure. We employ a general strategy of using both Mtb and the closely related M. smegmatis (Ms) enzymes for structural and functional studies because of the usually better solubility of the Ms enzymes. In the present paper, we present our initial structural and functional studies on IspD from both Mtb (MtIspD, 231 amino acids, 24 041.4 Da) and Ms (MsIspD, 222 amino acids, 22 377.6 Da); the two proteins share 64% sequence identity with each other.
Methods

Cloning and expression
Genes encoding MsIspD (MSMEG_6076) and MtIspD (Rv3582c) were PCR-amplified from genomic DNA and the GTG start codons of each were mutated to ATG in the process. Both genes were designed with C-terminal truncations consisting of three residues for MsIspD (Arg220, Gly221 and Ala222) and two residues for MtIspD (Arg230 and Gly231); a C-terminal His 4 tag was appended. The resulting constructs were ligated into the pEXP5-CT/TOPO expression vector (Invitrogen) and used to transform Escherichia coli BL21-AI competent cells (Invitrogen). Cells expressing MsIspD were grown at 310 K until an OD 600 of 1 was reached in growth medium (10 g l À1 yeast extract, 10 g l À1 tryptone, 2 g l À1 NaCl, 3 g l À1 Na 2 HPO 4 , 2 g l À1 glycerol) with 100 mg ml À1 ampicillin. Protein expression was induced by adding 0.2 g l À1 l-arabinose and the cells were further incubated at 310 K for 3 h. Cells expressing MtIspD were grown at 310 K until an OD 600 of 0.6 was reached in Luria-Bertani medium with 100 mg ml À1 ampicillin. Protein expression was induced by adding 0.2 g l À1 l-arabinose and the cells were further incubated at 295 K for 12 h.
Protein purification
The cells were harvested by centrifugation and resuspended in lysis buffer (100 mM HEPES, 200 mM NaCl, 50 mM NaH 2 PO 4 , 50 mM Na 2 SO 4 , 10 mM imidazole, 0.5%(v/v) Triton X-100, final pH 7.5) with 0.05 mg ml À1 lysozyme, 0.01 mg ml À1 RNase, 0.02 mg ml À1 DNase I and 0.02 mg ml À1 phenylmethylsulfonyl fluoride. Cells were lysed in a cell disruptor (Constant Systems Ltd, UK) and cell debris was removed by centrifugation. The His-tagged proteins were purified from the supernatant on an Ni 2+ -NTA (Qiagen) column and immediately precipitated by adding ammonium sulfate to a final concentration of 3 M. The sample was centrifuged and the resulting protein pellet was dissolved in 100 mM HEPES, 10%(w/v) glycerol, 200 mM Na 2 SO 4 , 20 mM MgSO 4 (final pH 7.0). The proteins were further purified using a Superdex 75 (GE Healthcare) size-exclusion column. Fractions containing protein of the correct size were pooled and determined to be $99% pure by SDS-PAGE. The His 4 tag was retained on both proteins during all further studies.
Enzymatic assay
The activity of MtIspD in the conversion of MEP and CTP to CDP-ME and PP i was evaluated in a coupled assay (Bernal et al., 2005) . When the product PP i is hydrolysed by inorganic pyrophosphatase, the P i forms a complex with malachite green that can be detected at 620 nm.
A dephosphorylation method (Kö tting et al., 2009 ) was used to estimate the concentration of the substrate MEP (generously provided by AstraZeneca India Pvt. Ltd). This experiment was performed using the same setup as the assay described below. Each reaction contained 150 U ml À1 antarctic phosphatase (New England BioLabs), 1Â antarctic phosphatase buffer (New England BioLabs) and MEP (five different concentrations from 5 to 86 mM). Corresponding blanks were performed without antarctic phosphatase. The reactions were incubated at 310 K and samples were taken after 2 and 4 h to confirm that the reaction had progressed to completion. The MEP concentration was thus estimated on the basis of the amount of phosphate produced, assuming 95% conversion, as described by Kö tting et al. (2009) .
The inorganic pyrophosphatase-coupled assay was conducted at 293 K. The standard reaction mixture consisted of 50 mM HEPES-KOH pH 8.0, 10 mM MgCl 2 , 0.2 U ml À1 inorganic pyrophosphatase (Roche), MEP, CTP (Fluka) and 20 nM MtIspD (as determined by Bradford analysis using bovine serum albumin as standard). When varying MEP (nine different concentrations from 5.7 to 513 mM after correction), research papers the CTP concentration was kept at 250 mM. When varying CTP (ten different concentrations from 30 to 1200 mM), the MEP concentration was kept at 428 mM.
Each reaction was performed in a total volume of 300 ml and each corresponding blank reaction, which did not contain MtIspD, was performed in a total volume of 180 ml. All components except the enzyme were mixed and incubated for 10 min. The reactions were then initiated by adding MtIspD (or 50 mM HEPES-KOH pH 8.0 in the case of the blanks).
For each separate experiment, duplicate samples of 60 ml were taken from the reactions containing enzyme and a single sample from the blank reactions at two different time points (25 and 50 min) in order to ensure that initial velocities were being measured. To stop the reaction, each 60 ml sample was mixed with 15 ml malachite green solution (P i Colorlock Gold mix, Innova Biosciences) in a 96-well plate (SARSTEDT). After 5 min, 5 ml stabilizer (Innova Biosciences) was added to each well; after an additional 30 min, 120 ml H 2 O was also added before measuring the absorbance using a spectrophotometric plate reader (Envision 2140 Multilabel Reader, PerkinElmer). The production of inorganic phosphate was quantified by comparing the absorbance with that of a calibration curve for P i (standard solution provided with the P i Colorlock kit).
The K m and V max values were calculated by linear regression of the data plotted in the Lineweaver-Burk plot. The kinetic parameters presented for MEP and CTP are the averages from two and three separate experiments, respectively.
Crystallization
Crystallization trials were performed using the sitting-drop vapour-diffusion method at 293 K. An Oryx 6 robot (Douglas Instruments, UK) dispensed droplets (300 nl protein solution and 300 nl screening/reservoir solution) into MRC 2 Well plates (Molecular Dimensions, UK). The droplets were equilibrated against 80 ml reservoir solution.
Despite extensive crystallization screening of the full-length MsIspD and MtIspD proteins, no crystals were obtained. Therefore, slightly truncated versions of the proteins (see x2.1) were constructed: residues 1-219 for MsIspD and residues 1-229 for MtIspD. The C-terminal His 4 tag was retained on both proteins for crystallization screening. As with the full-length proteins, we screened the apo forms of the truncated constructs and as cocrystallizations with various ligands (CMP, CDP and CTP) with and without erythritol. The cofactor MgCl 2 was always included in the protein buffer at a molar excess (1-10 mM, depending on the protein concentration).
Crystals of MsIspD (at 40 mg ml À1 in 20 mM Bis-Tris propane pH 6.5, 0.1 M NaCl with 10 mM CTP and 1 mM MgCl 2 ) appeared in several conditions from the Morpheus screen (Molecular Dimensions, UK; Gorrec, 2009 ). The best diffracting crystals grew in condition E2, which consisted of 10%(w/v) PEG 8000, 20%(v/v) ethylene glycol, 0.03 M each of diethylene glycol, triethylene glycol, tetraethylene glycol and pentaethylene glycol and 0.1 M MES-imidazole buffer pH 6.5. Crystals as large as 0.3 Â 0.2 Â 0.2 mm grew overnight.
MsIspD (in the same buffer as above) also crystallized in the presence of 10 mM CMP, 10 mM MgCl 2 and 10 mM erythritol. These crystals were of similar dimensions and morphology. They appeared overnight in Morpheus condition B5 consisting of 10%(w/v) PEG 20 000, 20%(v/v) monomethyl ether PEG 550, 0.03 M NaF, 0.03 M NaI, 0.03 M NaBr and 0.1 M MOPS-Na HEPES pH 7.5.
Crystals of MtIspD (at 10 mg ml À1 in 20 mM Bis-Tris propane pH 6.5, 0.1 M NaCl with 10 mM CTP and 1 mM MgCl 2 ) also grew from the Morpheus screen. Crystals appeared after one week as clusters of rods with maximum dimensions 0.2 Â 0.1 Â 0.1 mm from condition A9 consisting of 10%(w/v) PEG 20 000, 20%(v/v) monomethyl ether PEG 550, 0.03 M CaCl 2 , 0.03 M MgCl 2 and 0.1 M bicine-Trizma base pH 8.5.
The crystals were harvested directly from the crystallization plate and vitrified in liquid nitrogen without further cryoprotection.
Data collection and processing
Diffraction data for the MsIspD-CTP complex were collected using our in-house X-ray source (Rotaflex RTP300 RC, Rigaku) to a resolution of 2.4 Å and were used to solve the initial structure by molecular replacement (data not shown). A higher resolution data set for the same complex was collected from a single fresh crystal at the European Synchrotron Radiation Facility (ESRF), as were diffraction data for the MsIspD-CMP and MtIspD-CTP complexes. Diffraction data from the MsIspD crystals were indexed and integrated using MOSFLM (Leslie, 2006) and scaled with SCALA (Evans, 2006) , which are part of the CCP4 package . Diffraction data from the MtIspD crystal were indexed and integrated using XDS and scaled with XSCALE, which are part of the XDS program package (Kabsch, 2010) . Data-collection statistics are shown in Table 1 .
Structure determination and refinement
The structure of the MsIspD-CTP complex was solved by molecular replacement with the program Phaser (McCoy et al., 2007) using a search model that consisted of a truncated polyalanine model of an E. coli IspD (EcIspD; PDB code 1vgt; Badger et al., 2005) subunit, from which we omitted residues equivalent to Gly11-Ala20 and Leu129-Ala155. The structures of the MsIspD-CMP complex and the MtIspD-CTP complex were solved by molecular replacement with Phaser using the A chain of the refined MsIspD-CTP structure as a search model. The three structures were improved by multiple alternating cycles of crystallographic refinement with REFMAC5 (Murshudov et al., 2011) and interactive rebuilding using O (Jones et al., 1991) . Waters were included using the Water_add command in O, which makes use of the average carbonyl O atom three-dimensional electron-density profile. Because of the limited resolution of the MtIspD-CTP complex, tight noncrystallographic (NCS) restraints were applied to the compact domain (i.e. excluding the -meander 137-161 and the poorly defined active-site loop 180-191) and a suitable relative weighting of diffraction data and restraint terms was determined to limit overfitting during refinement, in which we aimed to keep R free constant while reducing the difference between R and R free . Final refinement statistics are shown in Table 1 .
Other methods
Structural figures were prepared in O and rendered in Molray (Harris & Jones, 2001) . Secondary-structure assignments were made with the Yasspa command in O and then edited with artistic license so as to more clearly show only the longest strands and helices.
Overall structural similarities were identified with DALI (Holm & Park, 2000) . Detailed structural comparisons were made using the Lsq commands in O with default C matching-pair cutoffs of 3.8 Å or a close-pair cutoff of 1.0 Å (Kleywegt & Jones, 1997) . Sequence alignment was performed with PRALINE (Simossis & Heringa, 2005) and the corresponding figure was produced with ALINE (Bond & Schü ttelkopf, 2009 ). Homology models of putative Pf IspD domains were produced using the Phyre server (Kelley & Sternberg, 2009 ). Solvent-accessible area calculations were performed with AREAIMOL, which is part of the CCP4 package of programs .
Results
Enzyme activity
Activity was measured using an inorganic pyrophosphatasecoupled assay (Bernal et al., 2005) , with MEP concentrations validated in a separate phosphatase-based procedure. Under the conditions used, MtIspD was estimated to have a K m value of 43.5 mM and a k cat value of Table 1 Data-collection and refinement statistics.
Values in parentheses are for the outer resolution shell.
MsIspD-CTP
MsIspD-CMP MtIspD-CTP (Kleywegt & Jones, 1996) . § § Ideal values from Engh & Huber (1991) . 5.4 min À1 when MEP was the variable substrate and a K m value of 45.5 mM and a k cat value of 6.3 min À1 when CTP was the variable substrate (see Fig. 2 and Table 2 ).
General comments on structural work
In our structural studies of mycobacterial enzymes, we have adopted a standard approach of studying both the Mtb enzyme and its Ms homologue. The enzymes usually share high sequence homology, but the Ms enzymes are often easier to work with, in particular because they are generally more soluble. In the case of IspD, however, we were unable to produce suitable crystals from either the full-length MsIspD or MtIspD enzymes. We therefore designed, cloned and expressed constructs with short C-terminal truncations based on sequence-structure alignments (Fig. 3 ). However, crystallization trials with these new constructs were unsuccessful until we carried out a buffer-optimization screen (Jancarik et al., 2004) . On the basis of this screen, the buffers for both IspD proteins were changed to Bis-Tris propane before concentration and crystallization screening. In this new buffer, both proteins crystallized readily in the Morpheus screen. A buffer-optimization screen had also been performed on the full-length versions of the proteins. We have to date been unable to crystallize any apo form of either the truncated or full-length proteins. It therefore seems that the truncations in the constructs, the inclusion of CTP or CMP and the optimized protein buffer were all critical in obtaining crystals.
Crystal structures of MsIspD have been determined in complex with CTP and with CMP. They were refined to crystallographic R factors of 18.5 and 18.1% at resolutions of 1.5 and 1.8 Å , respectively (Table 1 ). The natural sequence has been truncated by three residues at the C-terminus but was then extended with a His 4 tag. Both structures contained a dimer in the asymmetric unit and although both complexes crystallize in space group P2 1 2 1 2 1 they are non-isomorphous. The electron density of the CTP complex is well defined except for an active-site loop (residues 17-19) in the B chain, another loop nearby (residues 176-178 of both chains), the N-terminal methionine and the C-terminal histidine of the His 4 tag. Fig. 4 illustrates the quality of the electron density for this structure. In the CMP complex the loop around residue Ala176 is well defined in the A chain but not in the B chain. All four residues of the His tag have clear density in the B chain, while two are defined in the A chain; the N-terminal methionine, as expected, is missing in both chains. The temperature-factor distribution over the dimers is asymmetric in both crystal forms, such that the A chain has an average value that is $7 Å 2 lower. superimposed with an r.m.s.d. of 0.68 Å . NCS breaks down in some side-chain conformations, usually owing to poor electron density (e.g. the side chain of Arg150 is disordered beyond the C atom in the A chain of the CTP complex but is well defined in the B chain, where it stretches across the active site to the MEP-binding site). Pro159 has a well defined cis conformation in all chains. The few outliers from our strict-boundary Ramachandran definition (Kleywegt & Jones, 1996) are mostly localized to the relatively poorly defined loop around residue Ala176. However, residue Gln157 is a slight outlier in all four MsIspD chains that is in well defined electron density. This conformation allows the main-chain carbonyl O atom to accept a hydrogen bond from the side-chain amide O atom of the highly conserved ( Fig. 3) but buried residue Gln160.
MtIspD has been crystallized in complex with CTP, again in a non-isomorphous P2 1 2 1 2 1 space group, and the structure was refined to an R factor of 20.8% at 2.9 Å resolution (Table 1) . This also corresponds to a slightly truncated construct (residues 1-229) with a His 4 tag at the C-terminus and a dimer in the asymmetric unit. The electron density is well defined in both chains from residues 5 to 229 except for one of the activesite loops, in which we were unable to trace the segment 183-188; the last two residues of the His 4 tag are also missing from the model. Our final model includes a CTP and magnesium ion in each active site but, because of the limited resolution, no water molecules have been included. The complete dimer comparison, while showing an apparently exact twofold, gives an r.m.s.d. of 1.37 Å for 434 pairs of C atoms. The chain-to-chain superposition, however, shows a true rotation of 175.5 and an r.m.s.d. of 0.72 Å for the 221 equivalent C pairs. This crystal also shows temperaturefactor asymmetry, particularly in that the CTP and interacting loops have lower values in the A chain: $20 Å 2 versus $40 Å 2 .
MsIspD structures
As expected, the structure of MsIspD is similar to that of EcIspD (Richard et al., 2001) , with a single compact domain from which a long -meander extends (see Fig. 5 ). While each active site is created principally by residues from one compact domain (Fig. 5a ), some contributions also come from the twofoldrelated -meander, which is crucial to dimer formation (Fig. 5b) . The compact domain is a variation on the Rossmann fold (Rossmann et al., 1975) , with a classical nucleotide-binding unit combined with an additional strand, the sixth strand, which runs antiparallel to the rest of the strands in the -sheet. The seven-stranded sheet therefore has mixed directionality ordered 7-5-6 0 -4-1-2-3 (Richard et al., 2001) ; the -meander lies between the antiparallel strands 5 and 6 and consists of root, stem and tip regions. The meanders are critical to dimer formation because they intertwine around the local twofold axis. Each meander is involved in the formation of three well packed volume elements. Each tip and stem interacts with a twofold-related root and the final strand of the -sheet to form a five-stranded -barrel closed by the edge of helix 6. This volume is lined with branched-chain amino acids (Val126A, Val138B, Val144B, Val156A, Val193A and Ile195A) but also contains a cluster of polar side chains centred on Lys136B that interacts with the side chains of Asp181A, Glu187A and Thr147B (Fig.  6 ). Twofold-related meander stems and roots interact to form another -barrel containing branched side chains (Ile135 and Leu153) and proline rings (Pro131 and Pro148) ( Sequence alignments. Sequences of MsIspD, MtIspD, EcIspD and Pf IspD (UniProt identifiers A0R560, C6DMN4, C6UC96 and Q8I273, respectively) were aligned with PRALINE (Simossis & Heringa, 2005) and edited by hand to match the structural similarity where appropriate. We have included the secondarystructure definitions used in the main text, which were generated as described in x2. Secondary-structure elements are rainbow-coloured, as in chain A in the following figures. Numbering follows the M. smegmatis sequence. Only a portion of the PfIspD sequence is shown. Red triangles indicate the 22 residues highlighted by Kemp et al. (2003) . twofold axis. In total, dimer formation results in a net loss in solvent-accessible surface area of $3200 Å 2 .
Pairs of individual MsIspD subunits can be superimposed with r.m.s.d.s of $0.8 Å for $216 C pairs (Fig. 7a ). The only major difference is localized to the CMP-binding site in the B chain ( Fig. 7b ), which is described in more detail below. Smaller breakdowns in NCS are located in some of the connecting loops between secondary-structural elements (near residues Glu68, Ala176 and Gly190). Despite clear differences in crystallographic packing, the overall structures of the complete dimers in the CTP-bound and CMP-bound structures are very similar, with an r.m.s.d. of 0.81 Å over 434 C atoms when using a standard 3.8 Å pairwise cutoff.
CMP and CTP bind at the C-terminal edge of the main -sheet in a broad depression created by elements from both chains in the dimer. In the CTP complex, the cytosine base slots between the flat peptide planes of residues 10-11 and 78-79 found at the end of the first and third strands, respectively. Hydrogen bonds between the base and protein are made via main-chain (O2 to the amide N atom of residue Ala10, N4 to the carbonyl O atom of residue Gly76) and side-chain atoms (N3 to the hydroxyl of Ser82). The ribose has a C2-endo conformation, with the hydroxyl groups forming hydrogen bonds to main-chain atoms (O2 0 to amide nitrogen 11, O3 0 to carbonyl oxygen 8) and waters. In the CTP complex each triphosphate wraps around a magnesium ion, forming an octahedral coordination that is completed by three water molecules (Figs. 4 and 7b) . The side chains of three basic residues (Arg15, Lys22 and Lys204) form hydrogen bonds/salt links to the triphosphate, while the main-chain amide N atoms of residues 13-15 are hydrogen-bond donors. The CTPprotein interactions are essentially identical in each subunit of the dimer. In the CMP complex, however, there is a conformational change in the 12-25 loop (equivalent to the P-loop in nucleotide triphosphate hydrolases) of the B chain. In the A chain, therefore, the CMP is positioned and shares the same protein interactions as the cytosine and -phosphate of the CTP complex (Fig. 7b ). In the B chain, the CMP is shifted, almost as a rigid body, by more than 2 Å (Fig. 7b ). Despite this, local changes in the protein structure allow all hydrogenbonding interactions to the base to be maintained. Hydrogenbond interactions linking the protein with the ribose and -phosphate, however, are altered. The carbonyl O atom of residue Pro8 accepts a hydrogen bond from the O2 0 hydroxyl instead of that of O3 0 and while the interaction between the -phosphate and the Lys22 side chain is maintained, new hydrogen-bonding interactions between this phosphate and the amide N atom of Gly13 and the hydroxyl of Ser12 are made. The magnesium and erythritol that had been included in the crystallization of the CMP complex could not be identified in our electron-density maps. Representative electron density in the MsIspD-CTP structure. The A -weighted (2m|F o | À D|F c |) electron-density map (Read, 1986) is drawn at a level of 0.3 e Å À3 around the CTP-and Mg 2+ -binding site of MsIspD. The background cartoon has been created with the same red-blue rainbow colouring for one chain and a secondary-structure theme for the other (strands red, helices yellow and loops silver). The secondarystructure elements have been defined as described in x2.
Figure 5
Cartoons of the MsIspD-CTP structure. The views have been chosen (a) to illustrate the position of the active sites in the homodimer and (b) to show an overview of dimer formation. The twofold axis is drawn in each figure as a thin red cylinder. One chain has been drawn with rainbow colouring and the other with a secondary-structure theme.
MtIspD structure
Because of the relatively low resolution of the MtIspD-CTP complex, we used NCS restraints in the refinement of this crystal structure. It became apparent, however, that there was a breakdown in the NCS that affected the tip of the dimerforming -meander. With a close-pair alignment in the leastsquares superposition of the A and B chains, we can align 197 C pairs with an r.m.s.d. of 0.11 Å . 17 pairs in the region 140-156 are then separated by more than 1 Å and the five C atoms at the tip (residues 146-150) have differences of $3 Å . Despite the breakdown in NCS in MtIspD, the set of interactions made by the meanders around the dimer axis are very similar to those seen in MsIspD.
The CTP-and magnesium ion-binding sites are essentially identical in both chains, with interactions very similar to those that we observed in the MsIspD structure (Fig. 7b ). A minor difference concerns the substitution of Ser82 in MsIspD for Thr86 in MtIspD, where the conserved hydroxyl group makes a hydrogen bond to N2 of the base. Of the five insertions/ deletions in the aligned MsIspD/MtIspD sequences (Fig. 3) , two are at the termini, two more involve changes in links betweenand -units and one is in a loop close to the active site respectively) . This active-site loop is longer in the Mtb structure, but does not extend into the CTP-binding site. Indeed, the electron density is rather weak in the B chain and is not possible to interpret in the A chain.
During the final preparation of this manuscript an as yet unpublished MtIspD apoenzyme structure was deposited (PDB entry 3okr; J. C. Sacchettini, M. C. M. Reddy, J. B. Bruning & C. Thurman, unpublished work). This structure contains two dimers in the asymmetric unit in a P1 unit cell. The most striking differences compared with our MtIspD-CTP complex involve the loops making up the cytosine basebinding site. In all four chains much of the 'P-loop' is dis- Table 3 Structural comparisons with the MsIspD-CTP complex A chain using DALI.
In enzymes with more than one chain, the chain with the highest Z has been included. The Z score is the degree of structural similarity in standard deviations above that expected as reported by the DALI server (Holm & Park, 2000) . R.m.s.d. is the positional root-mean-square deviation of superimposed C atoms. lali is the total number of equivalent residues. nres is the length of the entire chain of the equivalent structure. %id is the percentage sequence identity over equivalent positions. 
Figure 6
MsIspD-CTP dimer interactions. The interacting side chains around the twofold axis (to the right of the figure) come from the -meanders, while the interactions to the left illustrate how the -meander stem from one chain interacts with the second chain in a small enclosed volume containing side chains of highly conserved residues. Because of symmetry, the latter set of interactions are duplicated within the dimer as a whole (not shown).
ordered (corresponding to residues 16-25), while the loop connecting the edge strand 3 to helix 3 is shifted by up to 1.5-3 Å . The separate chains of this apoenzyme structure can be superimposed on our CTP complex with r.m.s.d.s of $1.0 Å for $198 C pairs.
Relationship to earlier structures
The most significant breakthrough in the study of IspD came in 2001 with the publication of the E. coli structure in three states of complexation: the apoenzyme, the CTP (i.e. one substrate plus Mg 2+ ) complex and the CDP-ME (one product plus Mg 2+ ) complex (Richard et al., 2001) . As well as providing insights into the reaction mechanism, this work demonstrated that IspD shares structural similarity to a family of cytosine transferase enzymes. IspD is now classified as a member of glycosyl transferase clan GT-A and has been assigned to Cluster of Orthologous Groups (COG) 1211 (Tatusov et al., 1997) and Pfam family 01128 (Bateman et al., 2004) . Although EcIspD remains the best-studied of the IspD enzymes, struc-tures are also available for other IspDs, as detailed in Table 3 for the results of a structural similarity search using DALI (Holm & Park, 2000) . One, the Campylobacter jejuni enzyme, is an IspD/IspF fusion protein with both enzymatic activities. Another, TarI from Streptococcus pneumoniae, is an IspD-like protein that uses ribitol 5-phosphate as a substrate but also has activity towards MEP. As expected, mycobacterial IspDs show most similarity to the existing IspD structures and TarI. Single subunits from these enzymes can be superimposed on MsIspD with r.m.s.d.s in the range 1.8-2.3 Å for 195-218 pairs of C atoms. The variation in the number of matched pairs is a consequence in part of disordered regions in some of the crystal structures. The alignment of the E. coli enzyme (PDB entry 1i52 chain A; Richard et al., 2001) , for example, gives an r.m.s.d. of 1.80 Å for 218 of 222 pairs of C atoms and 36% structure-based sequence identity. The highest structure-based sequence identity is with the Thermus thermophilus enzyme (44%) and the lowest is with the Listeria monocytogenes enzyme (25%). Although all of the enzymes in this group form an active dimer as described above, there is some plasticity in the dimer interface (Gabrielsen et al., 2006) . If we compare MsIspD with TarI, for example, an extra twist of $13 is required to align the second chains of the dimers around a rotation axis passing through the dimer-forming -meander domains close to their twofold axis. A close-pair structural alignment (described in the x2) of 11 representative IspD structures (Fig. 8a) clearly indicates that the -sheet is highly conserved, as well as the root and stem sections of themeander. The loop following 4, the central strand of the -sheet, is mostly similar until the middle of the following helix 4. Likewise, 7 (at one of the edges of the sheet) is similar, as is the connecting loop to the C-terminal helix 7. In the pair of loops making up the binding site for the cytosine base the main-chain conformations are less tightly clustered. In one of these loops the section following 1 shows a great deal of variation in structure (e.g. in the A and B chains of the MsIspD-CMP complex described above), in length (e.g. by one residue when comparing MsIspD and the L. monocytogenes enzyme) and crystallographic order (apoenzymes often have a disordered local structure, but the structure of A. thaliana CMP also has a disordered section). The second loop in this site, connecting the 3 edge strand to the next helix 3, is well conserved in length and order but has local rigid-body shifts of up to 3 Å . In the MEP portion of the substratebinding site there is an even more striking asymmetry in the structural alignments. While the three strands at the edge of the -sheet (ordered 7-5-6) are very tightly clustered, the helices-containing loop connecting 6 and 7 shows a great deal of variation in structure and length, as do the tips of the -meander. Despite the variation in their length, the stem sections of the twofoldrelated -meanders are moderately well clustered where they help to form the MEP-binding site. However, the variation in positioning of the twofold axis in each dimer with respect to the structurally conserved regions means that there is no tight clustering of the dimer as a whole.
After the IspD group of enzymes, we find the closest member of the broader family of transferases: N-acetylglucosamine 1-phosphate uridyltransferase GlmU (Kostrewa et al., 2001) . Members of this family are larger, contain an extra -helix domain and form trimers (Brown et al., 1999) . Here, portions of the transferase domain of $205 amino acids can be superimposed with r.m.s.d.s of 2.4 Å and higher, while there is a drop in the structure-based sequence identity to 15% or less. As well as the overall fold, the location of the substrate-binding site is conserved. Although the products overlap remarkably well, the detailed interactions are different; in particular, the dimer-forming -meander is missing. After the GlmU structures, there is a long series of more distantly related nucleotide transferases (data not shown).
Discussion
Our measured kinetic parameters for MtIspD (Table 2) give calculated k cat /K m values of 125 mM À1 min À1 for MEP and 138 mM À1 min À1 for CTP. Our K m values are similar to those published previously for the same enzyme (Shi et al., 2007; Eoh et al., 2007;  see Table 2 ). However, a larger variation is seen among the k cat values. A sixfold lower k cat value for both substrates was reported by Eoh et al. (2007) . A possible explanation may be that the earlier experiment was conducted under nonsaturating conditions, since the concentration of the fixed substrate was held at less than twice its own K m while varying the other substrate. A smaller difference is seen when comparing with the values reported by Shi et al. (2007) . The variation here could arise from the use of a lower concentration of magnesium chloride (2 mM instead of 10 mM), which may lower the activity (Eoh et al., 2007) . A comparison with the kinetic parameters of EcIspD is even less straightforward because there is a large variation in the published results, as shown in Table 2 . However, the k cat for the EcIspD enzyme is consistently found to be higher than that obtained for MtIspD. In the EcIspD-CTP complex, Richard et al. (2001) showed the -phosphate to be directly coordinated by the guanido group of Arg20 (Arg15 and Arg20 in MsIspD and MtIspD, respectively). The main-chain N atom of the preceding residue, Arg19, also formed a hydrogen bond, an interaction that is conserved in the Ms and Mtb enzymes. While not making a direct salt link, the guanido group in the side chain of Arg19 had a closest approach of 4.2 Å to the -phosphate and was therefore suggested to be involved in stabilizing this group in the transition state. In both MsIspD and MtIspD the equivalent residue is a glutamic acid whose side chain points away from the -phosphate of CTP in our complexes. We suggest that the loss of transition-state stabilization caused by this sequence change may account, at least in part, for the smaller k cat value observed for MtIspD. Superposition of representatives of 11 IspD structures. The view has been chosen in (a) to illustrate the well conserved core sheet and to highlight the variation in the -meanders and some of the loops and helical segments discussed in the text. The high variability in helices 3, 5 and 6 is not apparent because we have applied a front-plane clipping action to remove them. In (b), the view has been chosen to highlight the structural variability. The superpositions were made with close-pair cutoffs as described in x2.
Alignment of the EcIspD sequence with those from eight bacterial pathogen species gave pairwise identities in the range 30-90%; 22 residues were strictly conserved, of which 21 are in the active site (Kemp et al., 2003) . All of these residues are conserved in MtIspD and MsIspD, as are the subset of these that are thought to take part in catalysis (Richard et al., 2001) . Therefore, it is not surprising that MsIspD and MtIspD have substrate-product binding sites that are very similar to those of the E. coli enzyme. In Fig. 9 , we have combined the structural results of the E. coli CDP-ME product complex with our MsIspD-CTP complex structure to show the disposition of these highly conserved residues and how they are likely to interact with substrates in both MsIspD and MtIspD. This superposition shows the following:
(i) A highly conserved set of interactions between protein and product. Interestingly, in our MsIspD-CTP complex, water molecules overlap the positions of the MEP hydroxyl groups, indicating that this part of the active site is preformed to interact with the substrate.
(ii) That four of the conserved residues are from the dimerrelated meander, of which two (Thr134 and Arg150) interact directly with the product (Richard et al., 2001) and presumably the MEP substrate, while the others (Lys146 and Thr147) help to create part of the dimer interface that we described earlier (Fig. 6) .
(iii) That there may be space for the extension of MEP by 2-3 non-H atoms.
(iv) A structurally well conserved cytosine-binding site that extends away from the magnesium-binding site. However, the variation that we observe within the IspD family as a whole and in the mycobacterial IspD structures in particular indicates some degree of flexibility in two loops in the apoenzyme. These loops must be correctly formed to produce the cytosine ring-binding site and this may be relevant for inhibitor design. It suggests, for example, that a fragment-based approach may not be successful.
The Plasmodium falciparum enzyme (PfIspD) is conspicuous by its absence from the list discussed earlier (Kemp et al., 2003) despite the requirement for IspD activity in this class of parasite. The likely protein (UniProt accession No. Q8I273), which is conserved in all Plasmodium species that have been sequenced, is much larger than the classical IspDs described above. The putative enzyme is 734 amino acids in length, with a region of $220 amino acids near the C-terminus that shows 19 and 16% sequence identity to the E. coli and Ms/Mtb IspD sequences, respectively (see Fig. 3 ). In some organisms, IspD and IspF exist as a covalently linked pair; in Mtb they are adjacent in the genome but are separated by a stop codon and a single-base frameshift. This Plasmodium gene, however, has no IspF-like sequence that we can identify. The conservation in the IspD-like sequence indicates that the residues making up the active site are part of a dimer-forming enzyme. This includes residues from the second subunit of the dimer that interact with the MEP substrate and the -meander itself (e.g. the Lys136-Asp181 salt link in the meander-dimer interface; MsIspD numbering; see Fig. 6 ), which appears to be extended by nine amino acids. In the -hairpin barrel, the key branchedchain hydrophobic residues Ile135, Leu153, Pro131 and Pro148 of MsIspD are matched to Ile, Ile, Ala and Ile residues in Pf IspD. The cis-proline signature of IspDs where the meander 'returns' to the sixth strand of the sheet is clearly conserved, as are the adjacent residues. Of the 22 residues highlighted by Kemp et al. (2003) , 17 are conserved in this putative PfIspD, including those from the stem of the -meander making up the major portion of the dimer interface (see Figs. 3, 6 and 9). The largest insert (of $25 residues) occurs in the long loop between the sixth and last -strands (probably between 5 and 6), which is the region with largest structural variability in Fig. 8 . With our alignment, this PfIspD domain would start at Tyr417 and end at Tyr682 (using equivalent MsIspD N-and C-terminal residues). Interestingly, this protein contains a highly polar stretch of $60 residues close to its mid-point, which prompted us to investigate the N-terminal region in more detail. Indeed, the Phyre server (Kelley & Sternberg, 2009 ) identified another region with low sequence identity to IspD structures. Since the alignment does not extend to the critical highly conserved proline signature, we have omitted the alignment from Fig. 3 . However, the possibility exists that PfIspD represents fused IspD domains connected by a polar linker.
Our primary interest in the IspD enzyme and MEP pathway is in fact to develop new inhibitors for lead development. The best IspD inhibitor that has been described to date in the literature, erythritol-4-phosphate, has a rather poor IC 50 of Highly conserved residues in the active site of a mycobacterial IspD. The MsIspD-CTP active site is shown with the CDP-ME product docked from the superimposed EcIspD complex of Richard et al. (2001) . Four residues come from the -meander of the twofold-related subunit. Dotted lines show expected hydrogen bonds. One conserved residue, Asp210, is neither in the active site nor involved directly in dimer formation; it appears at the top of the figure. 
